Maggie Aulsebrook completed her PhD studies at Monash University in 2017 with a thesis focused on the development of luminescent lanthanide chemosensors for the detection of biologically relevant species. Following this, she took up a position as a postdoctoral research fellow at Chimie ParisTech in the development of a library of compounds for the advancement of zirconium-89-based radiotracers for applications in PET. Maggie then joined ANSTO as a research radiochemist where she was involved in the development of the next generation of nuclear medicines for the diagnosis and therapy of human diseases. While at ANSTO her research spanned the development of novel radiopharmaceuticals for application in pre-clinical and clinical studies and in commercial production. To interface more closely with the clinic, Maggie moved to UCSF and focused on the development and clinical translation of GMP-grade research radiopharmaceuticals for first-in-human and investigational studies.
Maggie has returned to Monash University and is leading the Radiochemistry Platform at Monash Biomedical Imaging (MBI). Maggie specialises in the development and clinical translation of radiopharmaceuticals. Throughout her career, she has led the development of a number of investigational radiopharmaceuticals for first-in-human application and provides expertise in the lifecycle of radiopharmaceuticals for clinical application.
